Re-establishing a place for phage therapy in western medicine

Future Microbiology

Volumn 10, Issue 5, 2015, Pages 685-688

  Kutter, Elizabeth Martin ^a   Kuhl, Sarah J ^b   Abedon, Stephen T ^c  

^a EVERGREEN STATE COLLEGE   (United States)

^b Section of Gastroenterology   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

clinical phage trials; compassionate care; MRSA; phage therapy; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; DRUG SAFETY; EASTERN EUROPE; EDITORIAL; FRANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; WESTERN MEDICINE; BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); GROWTH, DEVELOPMENT AND AGING; PROCEDURES; UTILIZATION;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC;

EID: 84929742239     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.28     Document Type: Editorial

References (21)

1. Aryee A, Price N. Antimicrobial stewardship - can we afford to do without it? Br. J. Clin. Pharmacol. 79(2), 173-181 (2015).
2. Keen EC. A century of phage research: bacteriophages and the shaping of modern biology. BioEssays 37(1), 6-9 (2015).
3. Reardon S. Phage therapy gets revitalized. Nature 510(7503), 15-16 (2014).
4. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J. Clin. Invest. 124(10), 4212-4218 (2014).
5. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 8(6), 769-783 (2013).
6. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 1(2), 66-85 (2011).
7. Kutter E, De Vos D, Gvasalia G et al. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11(1), 69-86 (2010).
8. Kazmierczak Z, Gorski A, Dabrowska K. Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. Viruses 6(7), 2551-2570 (2014).
9. Abedon ST. Phage therapy of pulmonary infections. Bacteriophage 5(1), e1020260-1-e1020260-13 (2015).
10. Chanishvili N. A Literature Review of the Practical Application of Bacteriophage Research. Nova Publishers, NY, USA (2012).
11. Kutter E, Borysowski J, Miedzybrodzki R et al. Clinical phage therapy. In: Phage Therapy: Current Research and Applications. Borysowski J, Miedzybrodzki R, Górski A (Eds). Caister Academic Press, Norfolk, UK, 257-288 (2014).
12. Hagens S, Loessner MJ. Bacteriophage for biocontrol of foodborne pathogens: calculations and considerations. Curr. Pharm. Biotechnol. 11(1), 58-68 (2010).
13. Chan BK, Abedon ST. Bacteriophages and their enzymes in biofilm control. Curr. Pharm. Des 21(1), 85-99 (2015).
14. Borysowski J, Miedzybrodzki R, Górski A. Phage Therapy: Current Research and Applications. Caister Academic Press, Norfolk, UK (2014).
15. Abedon ST. Phage companies. www.companies.phage.org
16. Pirnay J-P, Verbeken G, Rose T et al. Introducing yesterday's phage therapy in today's medicine. Future Virol. 7(4), 379-390 (2012).
17. Eaton MD, Bayne-Jones S. Bacteriophage therapy: review of the principles and results of the use of bacteriophage in the treatment of infections (I). J. Am. Med. Assoc. 103, 1769-1776 (1934).
18. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr. Pharm. Biotechnol. 11(1), 28-47 (2010).
19. Kelly D, McAuliffe O, Ross RP, O'Mahony J, Coffey A. Development of a broad-host-range phage cocktail for biocontrol. Bioeng. Bugs 2(1), 31-37 (2011).
20. Bruynoghe R, Maisin J. Essais de thérapeutique au moyen du bactériophage du Staphylocoque. Compt. Rend. Soc. Biol. 85, 1120-1121 (1921).
21. MacNeal WJ, Frisbee FC, McRae MA. Staphylococcemia 1931-1940. Five hundred patients. Am. J. Clin. Pathol. 12, 281-294 (1942).